AI Engines For more Details: Perplexity Kagi Labs You
Anti-inflammatory Action: Zafirlukast belongs to a class of medications known as leukotriene receptor antagonists (LTRAs). It works by blocking the action of leukotrienes, which are inflammatory mediators produced by the immune system in response to allergens and other triggers. By inhibiting leukotriene activity, zafirlukast helps reduce inflammation in the airways, thereby alleviating symptoms of asthma and preventing asthma attacks.
Bronchodilation: In addition to its anti-inflammatory effects, zafirlukast also has a bronchodilator effect, which means it helps to relax and widen the airways in the lungs. By promoting bronchodilation, zafirlukast improves airflow and makes breathing easier for individuals with asthma.
Prevention of Asthma Symptoms: Zafirlukast is used as a maintenance therapy to prevent and control asthma symptoms, including wheezing, shortness of breath, chest tightness, and coughing. It is not intended for the relief of acute asthma attacks but rather for long-term management to reduce the frequency and severity of exacerbations.
Improvement in Lung Function: Treatment with zafirlukast has been shown to improve lung function, as evidenced by increases in peak expiratory flow rate (PEFR) and forced expiratory volume in one second (FEV1). These improvements indicate better airflow and respiratory function in individuals with asthma.
Reduction in Asthma Exacerbations: By reducing airway inflammation and bronchoconstriction, zafirlukast helps prevent asthma exacerbations and the need for rescue medications (e.g., short-acting beta-agonists) in many patients. It is often used as part of a comprehensive asthma management plan that may also include inhaled corticosteroids and other controller medications.
Allergic Rhinitis: Zafirlukast may also be used in the treatment of allergic rhinitis (hay fever) in some cases, particularly when asthma symptoms coexist with allergic nasal symptoms. By blocking the effects of leukotrienes, zafirlukast can help alleviate nasal congestion, sneezing, itching, and rhinorrhea associated with allergic rhinitis.
Side Effects: Common side effects of zafirlukast may include headache, gastrointestinal upset (e.g., nausea, diarrhea, abdominal pain), and liver enzyme abnormalities. Rare but serious side effects may include hepatic dysfunction, eosinophilic conditions (e.g., Churg-Strauss syndrome), and neuropsychiatric effects (e.g., mood changes, agitation, hallucinations). Patients should be monitored for signs of liver dysfunction and other adverse effects while taking zafirlukast.
Drug Interactions: Zafirlukast may interact with other medications, including certain antibiotics, antifungal agents, and anticoagulants, potentially affecting their effectiveness or increasing the risk of adverse reactions. It is important for healthcare providers to review a patient's complete medication list and medical history before prescribing zafirlukast to minimize the risk of drug interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium adolescentis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 4.8 | 0.6 | 7 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 0.4 | 1.75 |
| Allergic Rhinitis (Hay Fever) | 2.8 | 2.4 | 0.17 |
| Allergies | 5.5 | 2.9 | 0.9 |
| Allergy to milk products | 1.4 | 1 | 0.4 |
| Alopecia (Hair Loss) | 1.6 | 1.6 | |
| Alzheimer's disease | 4.6 | 6.5 | -0.41 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.4 | 0.3 | 7 |
| Ankylosing spondylitis | 3.6 | 1.5 | 1.4 |
| Anorexia Nervosa | 1.6 | 3.2 | -1 |
| Antiphospholipid syndrome (APS) | 1.5 | 1.5 | |
| Asthma | 5.6 | 2.3 | 1.43 |
| Atherosclerosis | 1.8 | 1.9 | -0.06 |
| Atrial fibrillation | 4.1 | 2.2 | 0.86 |
| Autism | 9.9 | 8.8 | 0.13 |
| Autoimmune Disease | 0.6 | 1 | -0.67 |
| Barrett esophagus cancer | 0.3 | 0.3 | 0 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 1.8 | 1.8 | |
| Bipolar Disorder | 1.5 | 1.7 | -0.13 |
| Brain Trauma | 0.9 | 1.4 | -0.56 |
| Cancer (General) | 0.6 | 3.4 | -4.67 |
| Carcinoma | 3.2 | 2.6 | 0.23 |
| Celiac Disease | 3 | 3.5 | -0.17 |
| Cerebral Palsy | 1.4 | 1.3 | 0.08 |
| Chronic Fatigue Syndrome | 5.7 | 7.1 | -0.25 |
| Chronic Kidney Disease | 4.6 | 2.6 | 0.77 |
| Chronic Lyme | 0.6 | 0.8 | -0.33 |
| Chronic Obstructive Pulmonary Disease (COPD) | 2.1 | 1.7 | 0.24 |
| Chronic Urticaria (Hives) | 0.8 | 1.2 | -0.5 |
| Coagulation / Micro clot triggering bacteria | 0.7 | 1.3 | -0.86 |
| Cognitive Function | 3.1 | 1.6 | 0.94 |
| Colorectal Cancer | 5.7 | 2.2 | 1.59 |
| Constipation | 1.5 | 0.7 | 1.14 |
| Coronary artery disease | 1.8 | 3 | -0.67 |
| COVID-19 | 10 | 13.5 | -0.35 |
| Crohn's Disease | 7.5 | 5.3 | 0.42 |
| Cushing's Syndrome (hypercortisolism) | 0.9 | -0.9 | |
| cystic fibrosis | 1.9 | -1.9 | |
| deep vein thrombosis | 0.9 | 1.4 | -0.56 |
| Denture Wearers Oral Shifts | 1.5 | 1.5 | |
| Depression | 11.2 | 8.7 | 0.29 |
| Dermatomyositis | 0.3 | 0.3 | 0 |
| Eczema | 1.4 | 2.6 | -0.86 |
| Endometriosis | 2.3 | 2 | 0.15 |
| Eosinophilic Esophagitis | 0.6 | -0.6 | |
| Epilepsy | 2.5 | 1.7 | 0.47 |
| erectile dysfunction | 0.5 | 0.3 | 0.67 |
| Fibromyalgia | 3.7 | 2.6 | 0.42 |
| Functional constipation / chronic idiopathic constipation | 5.7 | 4.9 | 0.16 |
| gallstone disease (gsd) | 3.1 | 0.8 | 2.88 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 1.5 | 1.2 | 0.25 |
| Generalized anxiety disorder | 1.9 | 2 | -0.05 |
| giant cell arteritis | 0.2 | -0.2 | |
| Glioblastoma | 0.3 | -0.3 | |
| Gout | 2.1 | 0.5 | 3.2 |
| Graves' disease | 1.9 | 3.3 | -0.74 |
| Gulf War Syndrome | 0.9 | 1.5 | -0.67 |
| Halitosis | 0.9 | 0.3 | 2 |
| Hashimoto's thyroiditis | 3.6 | 1.5 | 1.4 |
| Heart Failure | 3.4 | 1.9 | 0.79 |
| hemorrhagic stroke | 1 | 1 | |
| Hidradenitis Suppurativa | 0.9 | 0.3 | 2 |
| High Histamine/low DAO | 1.3 | 0.6 | 1.17 |
| hypercholesterolemia (High Cholesterol) | 0.5 | 0.5 | |
| hyperglycemia | 1.2 | 1.1 | 0.09 |
| Hyperlipidemia (High Blood Fats) | 0.6 | 0.3 | 1 |
| hypersomnia | 0.4 | -0.4 | |
| hypertension (High Blood Pressure | 4.1 | 5.2 | -0.27 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 2.4 | 0.3 | 7 |
| IgA nephropathy (IgAN) | 1.6 | 5.3 | -2.31 |
| Inflammatory Bowel Disease | 7.8 | 9.5 | -0.22 |
| Insomnia | 2.5 | 2.4 | 0.04 |
| Intelligence | 1.4 | 0.6 | 1.33 |
| Intracranial aneurysms | 1.2 | 0.6 | 1 |
| Irritable Bowel Syndrome | 7.1 | 5.3 | 0.34 |
| ischemic stroke | 2.6 | 1.1 | 1.36 |
| Liver Cirrhosis | 6.3 | 3.1 | 1.03 |
| Long COVID | 7.4 | 8 | -0.08 |
| Low bone mineral density | 1.1 | -1.1 | |
| Lung Cancer | 0.6 | 1 | -0.67 |
| Mast Cell Issues / mastitis | 0.3 | 0.9 | -2 |
| ME/CFS with IBS | 1.1 | 2.4 | -1.18 |
| ME/CFS without IBS | 2 | 2.4 | -0.2 |
| membranous nephropathy | 0.3 | 0.3 | |
| Menopause | 2.1 | 0.5 | 3.2 |
| Metabolic Syndrome | 6.6 | 7.3 | -0.11 |
| Mood Disorders | 11.1 | 7.8 | 0.42 |
| multiple chemical sensitivity [MCS] | 1.2 | 0.1 | 11 |
| Multiple Sclerosis | 6.7 | 6.7 | 0 |
| Multiple system atrophy (MSA) | 0.7 | 0.7 | 0 |
| myasthenia gravis | 0.3 | 0.7 | -1.33 |
| neuropathic pain | 0.3 | 2.6 | -7.67 |
| Neuropathy (all types) | 0.7 | 1.6 | -1.29 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 5 | 4.8 | 0.04 |
| NonCeliac Gluten Sensitivity | 1.3 | 0.6 | 1.17 |
| Obesity | 8.8 | 8 | 0.1 |
| obsessive-compulsive disorder | 5.8 | 4.2 | 0.38 |
| Osteoarthritis | 2.7 | 1.2 | 1.25 |
| Osteoporosis | 1.9 | 1.3 | 0.46 |
| pancreatic cancer | 0.6 | 0.3 | 1 |
| Parkinson's Disease | 7.4 | 7.4 | 0 |
| Polycystic ovary syndrome | 7 | 2.9 | 1.41 |
| Postural orthostatic tachycardia syndrome | 0.2 | 0.6 | -2 |
| Premenstrual dysphoric disorder | 0.7 | 0.4 | 0.75 |
| primary biliary cholangitis | 1.2 | 1.4 | -0.17 |
| Primary sclerosing cholangitis | 2.7 | 3.2 | -0.19 |
| Psoriasis | 3.3 | 3.4 | -0.03 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 7.6 | 4.4 | 0.73 |
| Rosacea | 1.2 | 0.7 | 0.71 |
| Schizophrenia | 6.7 | 3.1 | 1.16 |
| scoliosis | 0.3 | 0.7 | -1.33 |
| Sjögren syndrome | 2.6 | 3.2 | -0.23 |
| Sleep Apnea | 1.9 | 1.8 | 0.06 |
| Slow gastric motility / Gastroparesis | 0.9 | 0.3 | 2 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 1.4 | 0.6 | 1.33 |
| Stress / posttraumatic stress disorder | 2.3 | 2.7 | -0.17 |
| Systemic Lupus Erythematosus | 3.7 | 2.4 | 0.54 |
| Tic Disorder | 1.5 | 1.8 | -0.2 |
| Tourette syndrome | 0.9 | 0.3 | 2 |
| Type 1 Diabetes | 3.6 | 4.4 | -0.22 |
| Type 2 Diabetes | 8.2 | 7 | 0.17 |
| Ulcerative colitis | 5.2 | 6.9 | -0.33 |
| Unhealthy Ageing | 5.6 | 2.4 | 1.33 |
| Vitiligo | 2.5 | 1.5 | 0.67 |
